BackIntellia Therapeutics Overview

Intellia Therapeutics Current Cash

Latest current cash for NTLA: $110M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$106.13M
↓ 32.04% YoYΔ $-50.04M vs prior year quarter

Peer trimmed avg / median

Loading

Intellia Therapeutics Current Cash History

Loading

Intellia Therapeutics vs. peers: Current Cash Comparison

Loading

Intellia Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Intellia Therapeutics (NTLA) FAQ

As of the most recent data (June 2026), NTLA shows a current cash of $110M. That compares with $160M in the prior-year period — down 32.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NTLA's current cash is now $110M (was $160M) — a 32.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Intellia Therapeutics is outperforming or lagging.

Tracking NTLA's current cash over time shows whether Intellia Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $160M in the prior-year period — down 32.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Intellia Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $110M) with ownership activity and broader fundamentals.

Intellia Therapeutics's current cash is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.